Calliditas Therapeutics AB and, a commercial biopharma company focused on rare diseases announced that Renee Aguiar-Lucander, CEO of Calliditas will participate in the following March 2024 conferences.
STOCKHOLM, March 1, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) and (Nasdaq Stockholm: CALTX) (“Calliditas”), a commercial biopharma company focused on rare diseases today announced that Renee Aguiar-Lucander, CEO of Calliditas will participate in the following March 2024 conferences.
Carnegie Healthcare Seminar, Wednesday, March 6, 2024. Fireside chat will be held at 10:20 - 10:50 am CET and one-on-one meetings will be available.
Jefferies Biotech on the Bay Summit, Wednesday, March 13, 2024 in Miami, FL, one-on-one meetings will be available.
Leerink Partners Global Biopharma Conference on March 12, 2024 in Miami, FL.
For further information, please contact:
Åsa Hillsten, Head of IR & Sustainability, Calliditas
Tel.: +46 76 403 35 43, Email: asa.hillsten@calliditas.com
The information was sent for publication, through the agency of the contact person set out above, on March 1, 2024, at 13:00 CET.
The following files are available for download:
| PM_March Events_ENG |
View original content:https://www.prnewswire.com/news-releases/calliditas-therapeutics-to-attend-investor-conferences-in-march-302077149.html
SOURCE Calliditas Therapeutics
Company Codes: Stockholm:CALTX, NASDAQ-NMS:CALT, Bloomberg:CALT@US, Bloomberg:CALTX@SS, ISIN:SE0010441584, RICS:CALT.A, RICS:CALTX.ST
